GW Participating in the First Human Trial of mRNA-based HIV Vaccine

January 27, 2022

The George Washington University is one of four US sites conducting a Phase I clinical trial to test the safety and immune responses of two mRNA vaccine antigens for HIV on 56 healthy adults. The GW Vaccine Research Unit is running one of the study sites and acting as the processing lab and biorepository. The unit has partnered with study sponsor IAVI on two other HIV vaccine-related Phase I clinical trials and conducted several other clinical vaccine trials, including one for the FDA-authorized COVID-19 vaccine. Continue reading to see more about what GW is doing for the First Human Trial of mRNA-based HIV Vaccine.

Latest News

August 31, 2023
George Washington's Vaccine Research Unit is participating in the Project NextGen clinical study. Read this article on the journey to preparing the vaccines and treatments for the next outbreak.
April 20, 2023
Read more information about how The George Washington Vaccine Research Unit is looking for adolescents between the ages of 12 and 17 to participate in a Mpox vaccine trial. The need for adolescents is vital for researchers to get an approved vaccine for adolescents to prevent another outbreak.
December 8, 2022
Read more about the new hope found in Phase 1 clinical trials for the HIV vaccine.